Hemostasis diagnostics can detect hemostatic disorders that lead to excessive bleeding. Blood changes from a liquid to a gelatinous state during hemostasis. Hemostasis is a protective mechanism that the body goes through after an injury to stop blood flow and limit blood loss. Vasoconstriction, platelet plug formation, and blood coagulation are the next three phases. Hemostasis aids in the diagnosis and treatment of many illnesses by assisting in the determination of the underlying cause. The concept of automation has been used to hemostasis diagnostics, making them less labor-intensive, faster, and easier to use. Automated blood coagulation analyzers, flow cytometers, microarrays, and PCRs are examples of current technologies.

COVID-19 Impact Assessment

There were no particular diagnostic tests available to detect COVID-19 in patients during the early stages of the epidemic. Initially, alternative diagnostic tests were attempted, but they were ineffective. The lack of particular COVID-19 diagnostic tests presented diagnostic companies with profitable potential to create COVID-19 diagnostic kits. COVID-19 diagnostics kits were brought into local and global markets by a number of significant firms as well as certain start-ups from various nations. These companies had an advantage over other diagnostics companies by capitalising on the need for COVID-19 diagnostic tests, which helped them maintain income during the crisis. COVID-19 is predicted to have a substantial impact on the hemostasis diagnostics market as a result of these considerations.

Access Full Report Here : https://www.zionmarketresearch.com/report/hemostasis-diagnostics-market

Market Developments

Hemonetics announced the acquisition of Enicor, a developer of next-generation whole blood coagulation testing systems, for an unknown sum in April 2020. Enicor, based in Munich, Germany, creates the ClotPro system for viscoelastic diagnostics, which is said to include more assays than any other hemostasis analyzer on the market. ClotPro will be compatible with Haemonetics' TEG 5000 hemostasis analyzer and TEG 6s hemostasis analyzer with site-of-care technology, according to the company.

The ability of the body to clot blood is affected by coagulation diseases. Thrombosis or bleeding can occur as a result of certain conditions. Coagulatory abnormalities can be caused by a variety of factors. These conditions can be acquired or evolve over time.

Platelet dysfunction, von Willebrand disease, and haemophilia are some of the most common coagulation illnesses that can cause bleeding. In addition, coagulation disorders such as disseminated intravascular coagulation, vitamin K deficiency, and other clotting factor abnormalities can induce bleeding. During the projected period, these factors are expected to boost the worldwide hemostasis diagnostics market. Hemophilia A is four times more common than haemophilia B, according to the National Hemophilia Foundation. Hemophilia affects about 20,000 people in the United States.

HORIBA, Ltd., Abbott Laboratories, Siemens AG, and Bio-Rad Laboratories, Inc. are the major players in the Hemostasis Diagnostics Market. U.S. Beckman Coulter offers high-end and low-end analyzers to fulfil the needs of every haematology testing setting. Becton, Dickinson & Company, Grifols S.A, Alere, Inc., F. Hoffmann-La Roche AG, Beckman Coulter Inc., Sekisui, Helena Labor, Chrono-Log, and Axis-Shield are among the other suppliers that have used optimal product models, business expansion, and market appeal methods.

By Product Type: Laboratory Systems, Consumables, Point-of-Care Testing Systems

By Application: Hospital/Clinics, Independent Diagnostic, Laboratories, Other

Read More : https://www.zionmarketresearch.com/news/hemostasis-diagnostics-market

Demand for Hemostasis Diagnostics from 2016 to 2020 vs. Future Market Outlook for 2021 to 2031

The global market for hemostasis diagnostics was assessed at US$ 2 billion in 2020, according to market research and competitive intelligence company, and is expected to grow at a CAGR of roughly 7% to reach US$ 4 billion by 2031.

Hemostasis diagnostics aid in the detection of hemostatic flaws that result in excessive bleeding. A key element driving market expansion is the rising prevalence of blood clotting in patients, particularly those who are more prone to losing excess blood from the body after procedures.

Increased awareness of hemostasis disorders is likely to enhance diagnosis rates and preventative care management, resulting in a significant rise in testing volumes. Many novel diagnostic systems and tests, such as automated blood coagulation analyzers, have been introduced as a result of technological improvements, creating considerable potential opportunities for market participants.